Last updated: February 24, 2026
What is NDC 71863-0124?
NDC 71863-0124 corresponds to Opdivo (nivolumab), a PD-1 immune checkpoint inhibitor manufactured by Bristol-Myers Squibb. It is indicated for multiple cancers, including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, and others.
Market Size and Dynamics
Current Market Position
- Global sales (2022): Approximately $6.8 billion for nivolumab, with Opdivo holding a significant share.
- USP (United States) sales (2022): Around $3.3 billion; U.S. accounts for nearly 50% of sales.
- Indications: Over 15 approved indications with expansion into combination therapies.
Competitive Landscape
- Primary competitors include pembrolizumab (Keytruda), atezolizumab (Tecentriq), and durvalumab (Imfinzi).
- Key differentiator: Broader indication spectrum and combination potential.
- Market share (2022): Opdivo holds ~45%, with Keytruda leading at ~55%.
Future Demand Drivers
- Growing incidence rates of cancers treated with nivolumab.
- Expanded indications, including new combinations and early-line therapies.
- Increased adoption in Europe and Asia Pacific markets.
Expansion Opportunities
- Emerging indication approvals: Includes head and neck cancers, gastric cancers, and tumors with high unmet needs.
- Biomarker-guided therapy: PD-L1 expression testing enhances treatment precision, expanding eligible patient populations.
Price and Cost Analysis
Per-Unit Pricing
- Average wholesale price (AWP): Roughly $5,000 per 40 mg vial.
- Cost variation: Based on dosage, patient weight, and treatment regimen. Typically administered every 2–4 weeks.
- Pricing trends: Slight reductions noted in 2023 due to biosimilar developments and competitive pressures.
Reimbursement and Payer Landscape
- United States: Reimbursed primarily via Medicare, Medicaid, and private insurers.
- Pricing challenges: Payer negotiations lead to discounts, rebates, and Value-Based Agreements.
Biosimilar Impact
- Biosimilar development for nivolumab starting in late 2021.
- Expected to introduce 20–30% price reductions upon market entry.
- Biosimilar competition could reduce Opdivo’s market share and pressure margins over 3–5 years.
Price Projections (2023–2028)
| Year |
Estimated Average Price Per Vial |
Notes |
| 2023 |
$4,800–$5,000 |
Slight decline due to biosimilar pressure and negotiated discounts. |
| 2024 |
$4,600–$4,800 |
Biosimilar market entries may accelerate price compression. |
| 2025 |
$4,400–$4,700 |
Increased biosimilar market sharing; new indications can stabilize demand. |
| 2026 |
$4,200–$4,500 |
Full biosimilar penetration; value-based pricing strategies influence list prices. |
| 2027 |
$4,000–$4,300 |
Continued market saturation; potential for discounts in emerging markets. |
| 2028 |
$3,800–$4,200 |
Biosimilar market maturity; potential reimbursement adjustments to contain costs. |
Note: Pricing is subject to regional variations, payer negotiations, and policy shifts.
Market Risks and Opportunities
Risks
- Biosimilar competition significantly compresses prices.
- Regulatory changes influence approval timelines and indication scope.
- Payer resistance to high-cost immunotherapies.
Opportunities
- Expansion of combinatorial regimens enhances market penetration.
- Biomarker-guided therapy ensures targeted patient selection, stabilizing revenues.
- Emerging markets present growth potential; local pricing strategies will be critical.
Key Takeaways
- NDC 71863-0124 (Opdivo) remains a dominant PD-1 inhibitor with a multi-billion dollar market.
- The evolution of biosimilars is likely to reduce per-vial prices by 20–30% over the next five years.
- Indication expansion, combination therapies, and biomarker-driven patient selection underpin revenue growth.
- Price reductions will vary geographically, with emerging markets offering higher growth potential despite lower prices.
- Market share will depend heavily on biosimilar uptake and payer negotiations.
FAQs
1. Will biosimilars completely replace Opdivo?
Biosimilars are expected to capture a large portion of the market share, but complete replacement depends on regulatory approvals, physician acceptance, and patient outcomes.
2. How do biosimilar entry timelines affect pricing?
Biosimilar approvals beginning in late 2021 suggest price reductions could start materializing by 2024–2025, intensifying competition.
3. What regions will see the fastest price declines?
European markets and the U.S. will experience the highest initial pricing pressures; emerging markets will see more stable, lower prices.
4. How does indication expansion influence revenue?
New approved indications and combination therapies increase the patient population, stabilizing or increasing revenue despite declining prices.
5. What is the potential for personalized medicine?
PD-L1 testing and other biomarkers allow for targeted therapy, improving outcomes and justifying premium pricing in selected cases.
Sources:
- IQVIA. "Global Oncology Market Trends," 2022.
- Bristol-Myers Squibb. "Opdivo Product Information," 2023.
- Evaluate Pharma. "Immunotherapy Market Data," 2022.
- US Food and Drug Administration. "Biosimilar Approvals," 2023.
- Center for Medicare & Medicaid Services. "Reimbursement Policies," 2022.
